Susquehanna International Group, LLP Zentalis Pharmaceuticals, Inc. Put Options Transaction History

Susquehanna International Group, LLP

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$2.9 - $4.57 $95,700 - $150,810	33,000 New	33,000 $121,000
Q4 2023 Feb 14, 2024	BUY	$9.84 - $20.13 $125,952 - $257,664	12,800 Added 73.56%	30,200 $457,000
Q3 2023 Nov 14, 2023	SELL	$19.63 - $28.29 $363,155 - $523,365	-18,500 Reduced 51.53%	17,400 $349,000
Q2 2023 Aug 11, 2023	BUY	$17.41 - $30.05 $625,019 - $1.08 Million	35,900 New	35,900 $1.01 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $177M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.